Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices

Mitchell, A. J.; Delaffon, V.; Vancampfort, D.; Correll, C. U.; De Hert, M.

doi:10.1017/s003329171100105x

Cited by 332Schizophrenia research and treatmentHealth Promotion and Cardiovascular PreventionPsychiatric care and mental health services

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices

Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., De Hert, M.·2012·Psychological Medicine

DOI 10.1017/s003329171100105x

Open this paper in CoChat — free account

Abstract

Background: Despite increased cardiometabolic risk in individuals with mental illness taking antipsychotic medication, metabolic screening practices are often incomplete or inconsistent. Method: We undertook a systematic search and a PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) meta-analysis of studies examining routine metabolic screening practices in those taking antipsychotics both for patients in psychiatric care before and following implementation of monitoring guidelines. Results: We identified 48 studies (n=290 534) conducted between 2000 and 2011 in five countries; 25 studies examined predominantly schizophrenia-spectrum disorder populations; 39 studies (n=218 940) examined routine monitoring prior to explicit guidelines; and nine studies (n=71 594) reported post-guideline monitoring. Across 39 studies, routine baseline screening was generally low and above 50% only for blood pressure [69.8%, 95% confidence interval (CI) 50.9–85.8] and triglycerides (59.9%, 95% CI 36.6–81.1). Cholesterol was measured in 41.5% (95% CI 18.0–67.3), glucose in 44.3% (95% CI 36.3–52.4) and weight in 47.9% (95% CI 32.4–63.7). Lipids and glycosylated haemoglobin (HbA1c) were monitored in less than 25%. Rates were similar for schizophrenia patients, in US and UK studies, for in-patients and out-patients. Monitoring was non-significantly higher in case-record versus database studies and in fasting samples. Following local/national guideline implementation, monitoring improved for weight (75.9%, CI 37.3–98.7), blood pressure (75.2%, 95% CI 45.6–95.5), glucose (56.1%, 95% CI 43.4–68.3) and lipids (28.9%, 95% CI 20.3–38.4). Direct head-to-head pre–post-guideline comparison showed a modest but significant (15.4%) increase in glucose testing (p=0.0045). Conclusions: In routine clinical practice, metabolic monitoring is concerningly low in people prescribed antipsychotic medication. Although guidelines can increase monitoring, most patients still do not receive adequate testing.

Integrity signals

Registry

Crossref · 10.1017/s003329171100105x

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Screening for T2DM and cardiovascular disease (CVD) risk factors is still suboptimal, with only slight improvement over the last decade.
“screening for T2DM and CVD risk factors is still suboptimal, with only slight improvement over the last decade 12”
From Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis (2016) · cites this paper as [12]
The glucose screening rate in people with SMI is 44.3% (95% CI: 36.3%-52.4%).
“The low glucose screening rates (44.3%;95% CI: 36.3%-52.4%)12”
From Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis (2016) · cites this paper as [12]

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859 · see citing works
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955 · see citing works
Why Don't Physicians Follow Clinical Practice Guidelines?: A Framework for Improvement
Cabana, M. D., Rand, C. S., Powe, N. R., Wu, A. W., Wilson, M. H., Abboud, P.-A. C., & Rubin, H. R. (1999) · JAMA · doi:10.1001/jama.282.15.1458 · Cited by 6,677 · see citing works
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Self-citation
A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · see citing works
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554 · see citing works
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,334 · see citing works
Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.
(2006) · Europe PMC (PubMed Central) · Cited by 1,299 · see citing works
Successes and Failures in the Implementation of Evidence-Based Guidelines for Clinical Practice
Grol, R. (2001) · Medical Care · doi:10.1097/00005650-200108002-00003 · Cited by 1,233 · see citing works
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220 · see citing works
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., LAUGHREN, T. P., & Katz, R. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204 · see citing works
Factors influencing the implementation of clinical guidelines for health care professionals: A systematic meta-review
Francke, A. L., Smit, M. C., de Veer, A. J. E., & Mistiaen, P. (2008) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-8-38 · Cited by 1,131 · see citing works
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · see citing works
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870 · see citing works
Self-citation
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812 · see citing works
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · see citing works
Physical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633 · see citing works
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
Nasrallah, H. A., Meyer, J. M., GOFF, D. C., McEvoy, J. P., Thomas, S., Stroup, T. S., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.026 · Cited by 553 · see citing works
Gaps between knowing and doing: Understanding and assessing the barriers to optimal health care
Cochrane, L. J., Olson, C. A., Murray, S., Dupuis, M., Tooman, T., & Hayes, S. (2007) · Journal of Continuing Education in the Health Professions · doi:10.1002/chp.106 · Cited by 500 · see citing works
Medical complications of anorexia nervosa and bulimia nervosa
Mitchell, J. E., & Crow, S. J. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000228768.79097.3e · Cited by 492 · see citing works
What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews
Sheldon, T., Cullum, N. A., Dawson, D., Lankshear, A. J., Lowson, K., Watt, I. S., West, P. A., Wright, D., & Wright, J. (2004) · BMJ · doi:10.1136/bmj.329.7473.999 · Cited by 429 · see citing works
The effects of antipsychotic therapy on serum lipids: a comprehensive review
Meyer, J. M., & Koro, C. E. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.014 · Cited by 407 · see citing works
Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies
Mitchell, A. J., Malone, D., & Carney, C. P. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.045732 · Cited by 359 · see citing works
Self-citation
Disparities in Diabetes Care: Impact of Mental Illness
Frayne, S. M., Halanych, J. H., Miller, D. R., Wang, F., Lin, H., Pogach, L., Sharkansky, E. J., Keane, T. M., Skinner, K. M., Rosen, C. S., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.22.2631 · Cited by 336 · see citing works
Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges
Fleishhacker, W. W., Cetkovich-Bakmas, M., De Hert, M., Hennekens, C. H., Lambert, M., Leucht, S., Maj, M., McIntyre, R. S., Naber, D., Newcomer, J. W., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0401 · Cited by 328 · cited 1× · see citing works
“…problems and specifically metabolic and cardiovascular co-morbidity are recognized as being increasingly important in a range of severe mental illnesses (McIntyre et al. 2005 ; Mitchell & Malone, 2006 ; Leucht et al. 2007 ; Fleischhacker et al. 2008 ; Bresee et al. 2010a ; De Hert et al. 2011).”
Background
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
Smith, M. J., Hopkins, D., Peveler, R., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 274 · see citing works
From Silos To Bridges: Meeting The General Health Care Needs Of Adults With Severe Mental Illnesses
Horvitz-Lennon, M. V., Kilbourne, A. M., & Pincus, H. A. (2006) · Health Affairs · doi:10.1377/hlthaff.25.3.659 · Cited by 250 · see citing works
Mental disorders and quality of diabetes care in the veterans health administration.
Desai, M. M., Rosenheck, R., Druss, B., & Perlin, J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1584 · Cited by 238 · see citing works
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · see citing works
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome
Meyer, J. M., Nasrallah, H. A., McEvoy, J. P., GOFF, D. C., Thomas, S., Chakos, M., Patel, J. K., Keefe, R. S. E., Stroup, T. S., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.015 · Cited by 207 · see citing works
Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs
Morrato, E. H., Druss, B. G., Hartung, D. M., Valuck, R. J., Allen, R. R., Campagna, E. J., & Newcomer, J. W. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.179 · Cited by 199 · see citing works
Atypical antipsychotics and glucose dysregulation: a systematic review
Jin, H., Meyer, J. M., & Jeste, D. V. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.024 · Cited by 195 · see citing works
Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study.
Bresee, L. C., Majumdar, S., Patten, S., & Johnson, J. A. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.016 · Cited by 187 · see citing works
Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents
Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R. E., & Newcomer, J. W. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030383 · Cited by 178 · see citing works
Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes
Morrato, E. H., Newcomer, J. W., Kamat, S., Başer, O., Harnett, J., & Cuffel, B. J. (2009) · Diabetes Care · doi:10.2337/dc08-1720 · Cited by 171 · see citing works
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Barnett, A. H., Mackin, P., Chaudhry, I. B., Farooqi, A. M., Gadsby, R., Heald, A. H., Hill, J., Millar, H. L., Peveler, R., Rees, A., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107075509 · Cited by 166 · see citing works
Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers
Forsner, T., Hansson, J., Brommels, M., Wistedt, A. Å., & Forsell, Y. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-8 · Cited by 160 · see citing works
Efficacy of atypicalv.typical antipsychotics in the treatment of early psychosis: meta-analysis
Crossley, N. A., Constante, M., McGuire, P. K., & Power, P. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066217 · Cited by 153 · see citing works
Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis
Lord, O., Malone, D., & Mitchell, A. J. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.04.004 · Cited by 137 · see citing works
Self-citation
Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement
Lambert, T. J. R., & Chapman, L. H. (2004) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06443.x · Cited by 137 · see citing works
Quality of Diabetes Care Among Adults With Serious Mental Illness
Goldberg, R. W., Kreyenbuhl, J. A., Medoff, D. R., Dickerson, F., Wohlheiter, K. A., Fang, L., Brown, C. H., & Dixon, L. B. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.4.536 · Cited by 119 · see citing works
Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs
Paton, C., Esop, R., Young, C., & Taylor, D. M. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00372.x · Cited by 117 · see citing works
A Comparison of Type 2 Diabetes Outcomes Among Persons With and Without Severe Mental Illnesses
Dixon, L. B., Kreyenbuhl, J. A., Dickerson, F., Donner, T. W., Brown, C. H., Wolheiter, K., Postrado, L. T., Goldberg, R. W., Fang, L., Marano, C. M., et al. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.892 · Cited by 115 · see citing works
Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care
Lambert, T. J. R., & Newcomer, J. W. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02374.x · Cited by 115 · see citing works
Physical health and schizophrenia
Mitchell, A. J., & Malone, D. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000228767.71473.9e · Cited by 112 · see citing works
Self-citation
Extent and Management of Cardiovascular Risk Factors in Patients With Type 2 Diabetes and Serious Mental Illness
Kreyenbuhl, J. A., Dickerson, F., Medoff, D. R., Brown, C. H., Goldberg, R. W., Fang, L., Wohlheiter, K. A., Mittal, L. P., & Dixon, L. B. (2006) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000221177.51089.7d · Cited by 109 · see citing works
Review: Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis
Mitchell, A. J., & Lord, O. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382056 · Cited by 108 · see citing works
Self-citation
Élaboration de recommandations pour le suivi somatique des patients atteints de pathologie mentale sévère
Saravane, D., Fève, B., Francès, Y., Corruble, E., Lançon, C., Chanson, P., Maison, P., Terra, J.-L., & Azorin, J. (2009) · L Encéphale · doi:10.1016/j.encep.2008.10.014 · Cited by 105 · see citing works
Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs
Morrato, E. H., Newcomer, J. W., Allen, R. R., & Valuck, R. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0219 · Cited by 104 · see citing works
The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study
Yood, M. U., DeLorenze, G. N., Quesenberry, C. P., Oliveria, S. A., Tsai, A., Willey, V. J., McQuade, R. D., Newcomer, J. W., & L'Italien, G. J. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1781 · Cited by 103 · see citing works
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
Buckley, P. F., Miller, D. D., SINGER, B., ARENA, J., & Stirewalt, E. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.010 · Cited by 102 · see citing works
Quality of Diabetes Care Among Adults With Serious Mental Illness
Goldberg, R. W., Kreyenbuhl, J. A., Medoff, D. R., Dickerson, F., Wohlheiter, K. A., Fang, L., Brown, C. H., & Dixon, L. B. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.4.536 · Cited by 102 · see citing works
Off-Label Use of Antidepressant, Anticonvulsant, and Antipsychotic Medications Among Georgia Medicaid Enrollees in 2001
Chen, H., Reeves, J. H., Fincham, J. E., Kennedy, W. K., Dorfman, J. H., & Martin, B. C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0615 · Cited by 100 · see citing works
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study
Arango, C., Bobes, J., Aranda, P., Carmena, R., García-García, M., & Rejas, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.009 · Cited by 93 · see citing works
A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients
Mackin, P., Bishop, D. R., & Watkinson, H. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-28 · Cited by 88 · see citing works
Observation Interval for Evaluating the Costs of Surgical Interventions for Older Women With a New Diagnosis of Breast Cancer
Given, C. W., Bradley, C. J., Luca, A., Given, B. A., & Osuch, J. R. (2001) · Medical Care · doi:10.1097/00005650-200111000-00002 · Cited by 83 · see citing works
‘Schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3–4 October 2003: Consensus summary
(2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.47.s112 · Cited by 81 · see citing works
Belgian consensus on metabolic problems associated with atypical antipsychotics
Nayer, A. D., Hert, M. D., Scheen, A. J., Gaal, L. V., Peuskens, J., & on behalf of the Consensus Group (2005) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500510018310 · Cited by 80 · see citing works
Receipt of Diabetes Services by Insured Adults With and Without Claims for Mental Disorders
Jones, L. E., Clarke, W., & Carney, C. P. (2004) · Medical Care · doi:10.1097/00005650-200412000-00003 · Cited by 79 · see citing works
Diabetes Treatment Among VA Patients With Comorbid Serious Mental Illness
Krein, S. L., Bingham, C. R., McCarthy, J. F., Mitchinson, A., Payes, J. D., & Valenstein, M. M. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.7.1016 · Cited by 78 · see citing works
Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder
Kilbourne, A. M., Post, E. P., Bauer, M. S., Zeber, J. E., Copeland, L. A., Good, C. B., & Pincus, H. A. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.006 · Cited by 76 · see citing works
The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness
Holt, R., Abdelrahman, T., Hirsch, M., et al. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102788 · Cited by 76 · see citing works
Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme
Barnes, T. R. E., Paton, C., Hancock, E., Cavanagh, M.-R., Taylor, D. M., Lelliott, P. T., & Health, O. B. O. T. U. P. O. F. M. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01203.x · Cited by 75 · see citing works
[Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry].
Ruiz, J. S., García, J. B., Ruiloba, J. V., Ubago, J. G., & González, M. P. G.-P. (2008) · Actas Españolas de Psiquiatría · Cited by 74 · see citing works
Testing for diabetes in hospitalised patients prescribed antipsychotic drugs
Taylor, D. M., Young, C., Esop, R., Paton, C., & Walwyn, R. E. A. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.185.2.152 · Cited by 73 · see citing works
Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A cross-sectional study in a low cardiovascular disease risk geographical area
Bernardo, M., Cañas, F., Banegas, J. R., Casademont, J., Riesgo, Y., Varela, C., & On behalf of the RICAVA Study Group (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.07.010 · Cited by 67 · see citing works
Treatment of Cardiac Risk Factors Among Patients With Schizophrenia and Diabetes
Weiss, A. P., Henderson, D. C., Weilburg, J. B., GOFF, D. C., Meigs, J. B., Cagliero, E., & Grant, R. W. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.8.1145 · Cited by 61 · see citing works
Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs
Taylor, D. M., Young, C., Mohamed, R., Paton, C., & Walwyn, R. E. A. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105049039 · Cited by 59 · see citing works
The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management
Usher, K. J., Foster, K., & Park, T. (2006) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2006.01026.x · Cited by 58 · see citing works
Insulin sensitivity, adjusted β-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study
Oriot, P., Feys, J., de Wilmars, S. M., Misson, A., Ayache, L., Fagnart, O. C., Gruson, D., Luts, A., Jamart, J., Hermans, M. P., et al. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.03.003 · Cited by 55 · see citing works
Implementing a Physical Health Strategy in a Mental Health Service
Organ, B., Nicholson, E., & Castle, D. J. (2010) · Australasian Psychiatry · doi:10.3109/10398562.2010.506217 · Cited by 55 · see citing works
Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose?insulin homeostasis and lipid metabolism
Melkersson, K. I., Dahl, M., & Hulting, A. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1922-7 · Cited by 47 · see citing works
Swedish clinical guidelines—Prevention and management of metabolic risk in patients with severe psychiatric disorders
Gothefors, D., Adolfsson, R., Attvall, S., Erlinge, D., Jarbin, H., Lindström, K., von Hausswolff‐Juhlin, Y., Morgell, R., Toft, E., & Ösby, U. (2010) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2010.500397 · Cited by 46 · see citing works
Current Prescribing Patterns in Outpatient Child and Adolescent Psychiatric Practice in Central New York
Staller, J. A., Wade, M. J., & Baker, M. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.57 · Cited by 45 · see citing works
Monitoring and Management of Metabolic Risk Factors in Outpatients Taking Antipsychotic Drugs: A Controlled Study
Jennex, A., & Gardner, D. M. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300106 · Cited by 43 · see citing works
Awareness of Metabolic Concerns and Perceived Impact of Pharmacotherapy in Patients with Bipolar Disorder: A Survey of 500 US Psychiatrists
Suppes, T. M., McElroy, S. L., PhD, McElroy, S. L., MD, Hirschfeld, A. R., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4119 · Cited by 43 · see citing works
Metabolic Risk Factors Among Medicaid Outpatients With Schizophrenia Receiving Second-Generation Antipsychotics
Bell, R. C., Farmer, S., Ries, R. K., & Srebnik, D. S. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.12.1686 · Cited by 42 · see citing works
Monitoring and Prevalence Rates of Metabolic Syndrome in Military Veterans with Serious Mental Illness
Khatana, S. A. M., Kane, J., Taveira, T. H., Bauer, M. S., & Wu, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019298 · Cited by 42 · see citing works
“Medically Cleared”: How Well are Patients with Psychiatric Presentations Examined by Emergency Physicians?
Szpakowicz, M., & Herd, A. M. (2008) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2007.11.082 · Cited by 40 · see citing works
Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study
Voruganti, L. P., Punthakee, Z., VANLIESHOUT, R., MacCrimmon, D. J., PARKER, G., AWAD, A., & Gerstein, H. C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.016 · Cited by 39 · see citing works
Metabolic Risk Status and Second-Generation Antipsychotic Drug Selection
Morrato, E. H., Cuffel, B. J., Newcomer, J. W., Lombardo, I., Kamat, S., & Barron, J. O. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819294cb · Cited by 38 · see citing works
FDA to Require Diabetes Warning On Antipsychotics
Rosack, J. (2003) · Psychiatric News · doi:10.1176/pn.38.20.0001a · Cited by 37 · see citing works
Metabolic Adverse Events in Patients With Mental Illness Treated With Antipsychotics
Balf, G., Stewart, T. D., Whitehead, R. E., & Baker, R. A. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0104 · Cited by 36 · see citing works
Promoting Physical Health In Youth Mental Health Services: Ensuring Routine Monitoring of Weight and Metabolic Indices in a First Episode Psychosis Clinic
Hetrick, S. E., Álvarez‐Jiménez, M., Parker, A. G., Hughes, F., Willet, M. R., Morley, K. I., Fraser, R., McGorry, P. D., & Thompson, A. D. (2010) · Australasian Psychiatry · doi:10.3109/10398561003731189 · Cited by 35 · see citing works
Lipid Monitoring in Patients With Schizophrenia Prescribed Second-Generation Antipsychotics
Weissman, E. M., Zhu, C. W., Schooler, N. R., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0901 · Cited by 35 · see citing works
Atypical Antipsychotics in Psychiatric Practice: Practical Implications for Clinical Monitoring
Poulin, M.-J., Cortese, L., Williams, R. L., Wine, N., & McIntyre, R. S. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000909 · Cited by 35 · see citing works
Report and Recommendations Regarding Psychiatric Emergency and Crisis Services
Allen, M. H., Zealberg, J. J., & Currier, G. W. (2002) · Cited by 34 · see citing works
Awareness of Metabolic Concerns in Patients With Bipolar Disorder: A Survey of European Psychiatrists
Bauer, M., Lecrubier, Y., & Suppes, T. M. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.10.007 · Cited by 33 · see citing works
[Prevention and treatment of somatic complications arising from the use of antipsychotics].
Cahn, W., Ramlal, D., Bruggeman, R., de Haan, L., Scheepers, F. E., van Soest, M. M., Assies, J., & Slooff, C. J. (2008) · PubMed · Cited by 32 · see citing works
Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance
Moeller, K. E., Rigler, S. K., Mayorga, A., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.015 · Cited by 28 · see citing works
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
Shi, L., Ascher‐Svanum, H., Chiang, Y., Zhao, Y., Fonseca, V. A., & Winstead, D. K. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-80 · Cited by 28 · see citing works
Prediabetes Assessment and Follow-up in Older Veterans With Schizophrenia
Copeland, L. A., Parchman, M. L., Zeber, J. E., Lawrence, V. A., Downs, J. R., & Miller, A. L. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181e56cdc · Cited by 27 · see citing works
P.3.c.071 Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study
Hert, M. D., Falissard, B., Mauri, M., Shaw, K. M., & Wetterling, T. (2008) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(08)70655-2 · Cited by 23 · see citing works
Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia
Bresee, L. C., Majumdar, S. R., Patten, S. B., & Johnson, J. A. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.05.003 · Cited by 23 · see citing works
Change in psychiatrists’ attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia
Bobes, J., Alegría, A. A., Sáiz-González, M. D., Barber, I., Pérez, J. L., & Sáiz‐Ruiz, J. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.04.004 · Cited by 22 · see citing works
Retrospective Analysis of Diabetes Care in California Medicaid Patients with Mental Illness
Banta, J. E., Morrato, E. H., Lee, S. W., & Haviland, M. G. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0994-9 · Cited by 21 · see citing works
Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs–based population
Hsu, C., Ried, L. D., Bengtson, M. A., et al. (2008) · Journal of the American Pharmacists Association · doi:10.1331/japha.2008.07007 · Cited by 21 · see citing works
An Evaluation of Monitoring Practices in Patients on Second Generation Antipsychotics
Nguyen, D., Brakoulias, V., & Boyce, P. M. (2009) · Australasian Psychiatry · doi:10.1080/10398560902842519 · Cited by 21 · see citing works
From PORT to Policy to Patient Outcomes: Crossing the Quality Chasm
Pincus, H. A. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp142 · Cited by 19 · see citing works
Improving physical health monitoring for out-patients on antipsychotic medication
Gonzalez, C., Ahammed, N., & Fisher, R. (2010) · The Psychiatrist · doi:10.1192/pb.bp.108.021212 · Cited by 18 · see citing works
Development of a Health Screening Clinic
Millar, H. L. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71703-x · Cited by 18 · see citing works
Physician Patterns of Metabolic Screening for Patients Taking Atypical Antipsychotics
Motsinger, C. D., Slack, M., Weaver, M., & Reedr, M. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0405 · Cited by 16 · see citing works
Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities
Correll, C. U., Harris, J. L., Moya, R. A. P., Frederickson, A. M., Kane, J. M., & Manu, P. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.004 · Cited by 15 · see citing works
Self-citation
Comorbidités somatiques chez les patients souffrant de schizophrénie traitée. Recommandations actuelles
Lefèbvre, N., Chéreau, I., Schmitt, A., & Llorca, P. (2005) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2005.11.006 · Cited by 15 · see citing works
Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team
Crabb, J., McAllister, M., & Blair, A. (2009) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2009.00140.x · Cited by 14 · see citing works
Treatment Settings and Metabolic Monitoring for People Experiencing First-Episode Psychosis
Batscha, C. L., Schneiderhan, M. E., Kataria, Y., Rosen, C., & Marvin, R. W. (2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100730-03 · Cited by 14 · see citing works
Blood glucose testing for adults prescribed atypical antipsychotics in primary and secondary care
Tarrant, C. J. (2006) · Psychiatric Bulletin · doi:10.1192/pb.30.8.286 · Cited by 14 · see citing works
Monitoring the metabolic side-effects of atypical antipsychotics
Gumber, R., Abbas, M., & Minajagi, M. (2010) · The Psychiatrist · doi:10.1192/pb.bp.109.027433 · Cited by 11 · see citing works
Routine Laboratory Screening Among Newly Admitted Psychiatric Patients: Is It Worthwhile?
Cordón, R. D. A., Pérez-Rodríguez, M. M., Baca‐Baldomero, E., Oquendo, M. A., & Baca‐García, E. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.12.1602 · Cited by 10 · see citing works
A survey of monitoring of weight and blood glucose in in-patients
Boilson, M., & Hamilton, R. J. (2003) · Psychiatric Bulletin · doi:10.1192/pb.27.11.424 · Cited by 10 · see citing works
FDA Warns Of Suicide Risk With Paroxetine
Rosack, J. (2003) · Psychiatric News · doi:10.1176/pn.38.14.0001a · Cited by 8 · see citing works
A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia
Hert, M. D., Vancampfort, D., Correll, C. U., et al. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)73892-5 · Cited by 8 · see citing works
Self-citation
Do Antipsychotics Cost Lives or Save Lives? Risks Versus Benefits From Large Epidemiological Studies
Mitchell, A. J. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c1b44a · Cited by 8 · see citing works
Self-citation
Gender differences in metabolic monitoring of second‐generation antipsychotic prescription
Verdoux, H., Boulon, S., & Cougnard‐Grégoire, A. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.956 · Cited by 5 · see citing works
Letter
Mangurian, C. V., Goss, E., & Newcomer, J. W. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.11.1162 · Cited by 5 · see citing works
Consenso Brasileiro sobre antipsicóticos de segunda geração e distúrbios metabólicos Brazilian Consensus on second-generation antipsychotics and metabolic disorders
Elkis, H., Gama, C. S., Suplicy, H. D. L., et al. (2008) · Americanae (AECID Library) · doi:10.1590/s1516-44462008000100014 · Cited by 3 · see citing works
New Drug Offers Hope As Alzheimer’s Treatment
Rosack, J. (2003) · Psychiatric News · doi:10.1176/pn.38.9.0001a · Cited by 3 · see citing works
S24-01 - Neuroticism: an Intermediate Phenotype for Major Depression
Rujescu, D. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)70029-8 · Cited by 3 · see citing works
Opportunity for sub-specialty recruitment
Dixon, C. (2007) · Psychiatric Bulletin · doi:10.1192/pb.31.5.234 · Cited by 3 · see citing works
Blood glucose monitoring in a regional secure unit
Muthusamy, N., & D'Silva, K. (2007) · Psychiatric Bulletin · doi:10.1192/pb.31.5.234b · Cited by 2 · see citing works
Stress and eating disorders | [Stress e disturbi alimentari psicogeni]
Sauro, C. L., Ricca, V., Batini, S., Natrella, L., Lejeune, F., Rotella, F., Valgiusti, S., Bolognesi, E., Catena, M., & Faravelli, C. (2006) · Florence Research (University of Florence) · Cited by 2 · see citing works

Flagged first, then by citations

Sorted by citations

Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271 · see citing works
Self-citation
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659 · see citing works
Self-citation
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566 · see citing works
Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384 · see citing works
The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials
Vancampfort, D., Firth, J., Correll, C. U., Solmi, M., Siskind, D., De Hert, M., Carney, R., Koyanagi, A., Carvalho, A. F., Gaughran, F., et al. (2019) · World Psychiatry · doi:10.1002/wps.20614 · Cited by 227 · see citing works
Self-citation
Schizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214 · see citing works
Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis.
Galletly, C. A., Foley, D. L., Waterreus, A., Watts, G. F., Castle, D. J., McGrath, J. J., Mackinnon, A., & Morgan, V. A. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412453089 · Cited by 203 · see citing works
Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia.
Vancampfort, D., Probst, M., Scheewe, T., De Herdt, A., Sweers, K., Knapen, J., van Winkel, R., & De Hert, M. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.026 · Cited by 173 · see citing works
Self-citation
The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis
Stubbs, B., Eggermont, L., Mitchell, A. J., De Hert, M., Correll, C. U., Soundy, A., Rosenbaum, S., & Vancampfort, D. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12325 · Cited by 129 · see citing works
Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study
Correll, C. U., Joffe, B. I., Rosen, L. M., Sullivan, T. B., & Joffe, R. T. (2015) · World Psychiatry · doi:10.1002/wps.20187 · Cited by 102 · see citing works
Self-citation
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76 · see citing works
Reduced heart rate variability in schizophrenia and bipolar disorder compared to healthy controls
Quintana, D. S., Westlye, L. T., Kaufmann, T., Rustan, Ø. G., Brandt, C. L., Haatveit, B., Steen, N. E., & Andreassen, O. A. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12498 · Cited by 73 · see citing works
The prevention of diabetes and cardiovascular disease in people with schizophrenia
Holt, R. I. G. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12443 · Cited by 37 · see citing works
Diabetes, physical activity participation and exercise capacity in patients with schizophrenia
Vancampfort, D., De Hert, M., Sweers, K., De Herdt, A., Detraux, J., & Probst, M. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12077 · Cited by 34 · see citing works
Self-citation
Preventive service use among people with and without serious mental illnesses.
Yarborough, B. J. H., Perrin, N. A., Stumbo, S. P., Muench, J., & Green, C. A. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.08.020 · Cited by 13 · see citing works
The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients
De, R., Amin Alfatwa, Y., Kanagasundaram, P., Saragosa, J. E., Chan, J., Remington, G., Retnakaran, R., Sanches, M., Sockalingam, S., Agarwal, S. M., et al. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf236 · Cited by 1 · see citing works
“27 The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) trials 1 to 7 showed a mean body weight reduction ranging from 3.5 to 4.6 kg with semaglutide doses ranging from 0.5 to 1 mg weekly.”
Influential

Authors: Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M.
Affiliations: University of Leicester (GB)
Leicester General Hospital (GB)
KU Leuven (BE)
Albert Einstein College of Medicine (US)
Corresponding author: Mitchell, A. J.
ORCID: Mitchell, A. J.
Vancampfort, D.
Correll, C. U.
Venue: Psychological Medicine
Publisher: Cambridge University Press (CUP)
Published: 2011-08-10
Volume: 42
Issue: 1
Pages: 125-147
ISSN: 0033-2917 (ISSN-L)
1469-8978
DOI: 10.1017/s003329171100105x
OpenAlex: W2117209734
Cited by: 332
References: 122
Citations by year: 2026: 11 · 2025: 8 · 2024: 12 · 2023: 7 · 2022: 10 · 2021: 26 · 2020: 25 · 2019: 25 · 2018: 19 · 2017: 31 · 2016: 26 · 2015: 38 · 2014: 31 · 2013: 29 · 2012: 27
FWCI: 3.99
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified)
Locations: Psychological Medicine (publishedVersion)
PubMed (publishedVersion)
Lirias (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
Keywords: antipsychotic drugs, metabolic screening, cardiometabolic risk, guideline adherence, schizophrenia, blood pressure monitoring, lipid monitoring, glycaemic monitoring, weight monitoring, triglycerides, cholesterol, HbA1c, psychiatric inpatients and outpatients, psychiatric comorbidity
MeSH terms: Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Glycated Hemoglobin, Humans, Mass Screening, Risk Factors, Antipsychotic Agents, Practice Guidelines as Topic, Guideline Adherence, Metabolic Syndrome, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks